Crescent Biopharma (CBIO) Expected to Post Earnings on Thursday

Crescent Biopharma (NASDAQ:CBIO) will likely be announcing its results before the market opens on Thursday, November 5th. Analysts expect Crescent Biopharma to post earnings of ($0.6739) per share and revenue of $0.36 million for the quarter.

Crescent Biopharma Trading Down 4.2%

Shares of NASDAQ:CBIO opened at $12.91 on Tuesday. The business’s 50 day simple moving average is $15.54 and its two-hundred day simple moving average is $15.83. Crescent Biopharma has a 52-week low of $8.72 and a 52-week high of $27.41.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on CBIO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Crescent Biopharma in a report on Friday, August 7th. Wedbush reiterated an “outperform” rating and issued a $27.00 target price on shares of Crescent Biopharma in a report on Monday, September 14th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of Crescent Biopharma in a research report on Monday, October 19th. TD Cowen raised shares of Crescent Biopharma to a “strong-buy” rating in a research report on Monday, August 24th. Finally, UBS Group restated a “buy” rating and set a $36.00 price target on shares of Crescent Biopharma in a research note on Monday, October 19th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Crescent Biopharma presently has an average rating of “Buy” and a consensus target price of $33.00.

Insider Transactions at Crescent Biopharma

In other news, CEO Joshua T. Brumm sold 7,837 shares of the stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.71, for a total value of $130,956.27. Following the completion of the sale, the chief executive officer directly owned 271,765 shares of the company’s stock, valued at $4,541,193.15. This represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jonathan McNeill sold 3,839 shares of the stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.71, for a total value of $64,149.69. Following the completion of the sale, the chief operating officer directly owned 134,588 shares of the company’s stock, valued at approximately $2,248,965.48. This trade represents a 2.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 16,726 shares of company stock valued at $285,501 in the last quarter. Company insiders own 24.84% of the company’s stock.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.